It is still too early to determine any definitive federal policies for 2025 (or beyond) that could affect these companies. However, some analysts have speculated that the administration might restrict access to vaccines or even ban them outright, which would create a complex landscape for these firms.
Given this evolving environment, now is the time for investors to consider the strengths and opportunities presented by Eli Lilly, Pfizer, and AstraZeneca. Here's why these companies remain compelling investment options:
